Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653482 · ClinicalTrials.gov registry record · Phase 4
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
A Phase 4 study, sponsored by Saint Luke's Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 263
- Enrollment target
NCT02653482: Completed Phase 4 study, sponsored by Saint Luke's Health System.
NCT02653482 is a Phase 4 study that has completed, run by Saint Luke's Health System. The registered enrollment target is 263 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02653482, a Phase 4 study, has completed, sponsored by Saint Luke's Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 263 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.
Primary Outcome
Difference in the average of the 6- and 12-week mean N-terminal pro B-type natriuretic peptide (NTproBNP).
Interventions
- DRUG Dapagliflozin
- DRUG Dapagliflozin matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2016-03-03 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 4 |
What the finished NCT02653482 record still lists
NCT02653482 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT02653482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02653482 about?
NCT02653482 is a clinical study titled "Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure". The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.
What is the current status of trial NCT02653482?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 263 participants. The study started on 2016-03-03. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02653482?
The interventions under investigation include: Dapagliflozin (DRUG), Dapagliflozin matching placebo (DRUG).
Who is sponsoring clinical trial NCT02653482?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02653482's enrollment target sits among peer trials
263 323rd of 2000 higher than 1,678 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI